Zöller B, Zimmer M, Dittrich P, Lehmann K, Engel H J, Faust-Tinnefeldt G, Kukovetz W R
Z Rheumatol. 1983 Mar-Apr;42(2):78-81.
Patients suffering from rheumatoid arthritis received a single dose of the new therapeutic system of indomethacin (Gits 7/85). Samples of plasma and synovial fluid were taken after 1, 2, 4, 6, 8, 10, 12, and 24 h. Concentration peaks could not be observed. After 2-3 h plasma levels were achieved which remained constant over the investigational period. Indomethacin concentrations in synovial fluid were seen with some delay. All synovial fluid levels after single application were lower than the plasma concentrations. The kinetics of elimination showed no difference between the two compartments. The above findings confirm the expectations regarding the new therapeutic system of indomethacin (Gits 7/85), i.e., the maintenance of a nearly constant plasma and synovia level for at least 10 h. The avoidance of peaks is seen as an additional advantage.
患有类风湿性关节炎的患者接受了单剂量的吲哚美辛新治疗系统(Gits 7/85)。在1、2、4、6、8、10、12和24小时后采集血浆和滑液样本。未观察到浓度峰值。2-3小时后达到血浆水平,在研究期间保持恒定。滑液中吲哚美辛浓度出现稍延迟。单次给药后所有滑液水平均低于血浆浓度。两个隔室的消除动力学无差异。上述发现证实了关于吲哚美辛新治疗系统(Gits 7/85)的预期,即至少10小时维持几乎恒定的血浆和滑液水平。避免峰值被视为一个额外的优势。